A Clinical Appraisal of Pentapyrrolidinium (M&B 2050) in Hypertensive Patients
Here, Freis's team studied the effectiveness of pentapyrrolidinium (a ganglionic-blocking agent, also called pentolinium)
as an antihypertensive treatment. They concluded that the drug had several advantages in the treatment of severe hypertension
over another ganglionic-blocking agent, hexamethonium. The drug's attributes, longer duration of action, greater potency,
and a more uniform response to oral administration, more than compensated for its side effects and the frequent need to adjust
Number of Image Pages:
7 (954,891 Bytes)
1954-04 (April 1954)
Freis, Edward D.
Partenope, Edward A.
Lilienfield, Lawrence S.
Rose, John C.
Periodical: Freis, Edward D., Edward A. Partenope, Lawrence S. Lilienfield, and John C. Rose. "A Clinical Appraisal of Pentapyrrolidinium
(M&B 2050) in Hypertensive Patients." Circulation IX, 4 (April 1954): 540-546. Article. 7 Images.
[American Heart Association]
This item is in the public domain. It may be used without permission.
Medical Subject Headings (MeSH):
The Veterans Administration Hospital and Georgetown University School of Medicine, 1949-1964